Design of a Covalent Inhibitor for c-Myc-Dependent Cancers

描述（由申请人提供）：我们公司的主要商业目标是开发抑制人类致癌基因c-Myc的新疗法。C-Myc是一种主要的人类致癌基因，据估计至少导致70%的人类癌症，其中大多数是侵袭性的，对目前的治疗反应不佳。尽管经过了30多年的研究，抑制c-Myc的药物开发一直没有成功，因为这种蛋白质是一种转录因子，缺乏小分子结合的空间。因此，开发抑制c-Myc的新疗法被认为是推进癌症治疗的最重要目标之一。最近，包括我们在内的几个实验室的研究表明，小泛素样修饰（SUMO）对c- myc依赖性肿瘤的发生至关重要。我们最初的研究集中在结直肠癌上，因为这些癌症几乎100%依赖于c-Myc，转移性结直肠癌迫切需要新的治疗方法来提高患者的生存率。sumo化通过激活β -catenin/Tcf-4（结直肠癌中c-Myc表达的转录因子）对c-Myc表达很重要。在初步研究中，我们已经通过高通量筛选确定了一种非常特异性和有效的SAE抑制剂支架，即催化SUMO修饰的激活酶。用这种抑制剂抑制SUMOylation或通过敲低SAE显著降低结直肠癌细胞中的c-Myc水平。基于我们最近发现的先导化合物的新作用机制，我们设计了一些策略来提高其效力，这表明了一种易于处理的方法来增加其特异性、效力和作用时间。然后，我们将确定改进化合物的特异性和细胞机制，并将在动物模型中进行毒性和功效研究。我们的研究结果将显著推动这一领域的发展

DESCRIPTION (provided by applicant): The leading commercial goal of our company is to develop novel therapeutics to inhibit the human oncogene, c-Myc. C-Myc is a major human oncogene that is estimated to contribute to at least 70% of all human cancers, most of which are aggressive and respond poorly to current therapies. Despite more than 30 years of research, the development of drugs that inhibit c-Myc has been unsuccessful because the protein is a transcription factor that lacks pockets for small molecules to bind. Therefore, developing novel treatments that inhibit c-Myc is considered one of the most important goals for advancing cancer therapeutics. Recently studies from several laboratories including ours have shown that the small ubiquitin-like modifications (SUMO) are critical for c-Myc-dependent tumorigenesis. Our initial studies are focused on colorectal cancers, because these cancers are almost 100% dependent on c-Myc and new therapies are critically needed for metastatic colorectal cancers to improve patient survival. SUMOylation is important for c-Myc expression through activation of beta-catenin/Tcf-4, the transcription factor for c-Myc expression in colorectal cancers. In preliminary studies, we have identified a very specific and potent inhibitor scaffold of SAE, the activating enzyme that catalyzes SUMO modifications, using high throughput screening. Inhibition of SUMOylation with this inhibitor or by knockdown of SAE dramatically reduced c-Myc level in colorectal cancer cells. We have designed strategies to improve the potency of the lead compound based on our recent discovery of its novel mechanism of action, which indicates a tractable approach to increase its specificity, potency and duration of action. We will then determine the specificity and cellular mechanisms of the improved compounds and will conduct toxicity and efficacy studies in animal models. Our results will significantly advance the field by providing the first proof-of-concept in animal models that SUMOylation is a potential target to inhibit the c-Myc oncogene.